Company Overview of Albireo AB
Albireo AB, a biotechnology company, focuses on the development of therapeutic drugs for gastrointestinal diseases. It develops A3309, an oral compound for the treatment of patients with chronic idiopathic constipation. The company also develops A4250, a hepatology candidate for the treatment of primary biliary cirrhosis, progressive familial intrahepatic cholestasis, and alagille syndrome. Albireo AB was founded in 2008 and is based in Gothenburg, Sweden.
Arvid Wallgrens Backe 20
Gothenburg, 413 46
Founded in 2008
46 3 17 41 14 80
46 31 82 02 23
Key Executives for Albireo AB
Albireo AB Key Developments
Similar Private Companies By Industry
|Vitrolife Sweden AB||Europe|
|Lundonia Biotech AB||Europe|
|Berolina Drug Development AB||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Albireo AB, please visit www.albireopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.